Over forty years ago in a lab in Boston, biochemist Svetlana Mojsov made an astonishing discovery. She'd conjured up a mixture, GLP-1, that successfully increased insulin levels when blood sugars are high - a mammoth breakthrough for diabetes treatment. It's now the secret sauce in weight-loss drugs like Ozempic, which are taken by 1.6 million people. So why wasn't Mojsov recognised for her work? Why was she, like so many women before her, erased from the story?Guest: Aimee Donnellan, journalist and author 'Off the Scales: The Inside Story of Ozempic and the Race to Cure Obesity'.Host: Tom Whipple, science writer and special correspondent, The Times.Producer: Dave Creasey.Buy Aimee Donnellan's book from The Times BookshopClips: Sky NewsPhoto: Stephanie Diani for the Sunday Times Magazine.Get in touch: [email protected] podcast was brought to you thanks to subscribers of The Times and The Sunday Times. To enjoy unlimited digital access to all our journalism subscribe here. Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related